BioAffinity Technologies (BIAF) stock surged 20% premarket after a positive update on its AI-driven CyPath Lung test. The case study showed the test accurately identified low cancer risk in a patient with lung nodules, helping avoid invasive procedures. The test uses AI to analyse sputum for cancer signs. Over 4 million shares traded hands, significantly above the average.